Dr. Fried is Professor and Director of Translational Adipose Biology and Obesity in the Diabetes, Obesity and Metabolism Institute. She earned an A.B. in Biology from Barnard College (1974), a M.S. in Human Nutrition from the Institute of Human Nutrition, Columbia College of Physicians and Surgeons and a Ph.D. in Nutritional Biochemistry from Columbia University (1980). After post-doctoral work in Endocrinology at Emory University, and in Lipid Biochemistry at the Medical College of Pennsylvania, she returned to NYC to become a Research Associate at the New York Obesity Center. From 1986-1990, she was an Assistant Professor in the Laboratory of Human Behavior and Metabolism at Rockefeller University, followed by faculty positions at Rutgers University and the University of Maryland School of Medicine. At Maryland she was the founding director of a NIDDK-funded Clinical Nutrition Research Center. From 2009-2016 Dr. Fried was a Professor at Medicine and Biochemistry at the Boston University School of Medicine (BUSM). She was also the Director of the Graduate Program in Nutrition and Metabolism, and Director of the NIH NIDDK-funded Boston Obesity and Nutrition Research during this time. Her work has been well-funded by the NIH and the American Diabetes Association, among others, for the past 25 years.
Education
AB, Barnard College
MS, Columbia Univ. Institute of Human Nutrition
PhD, Columbia University
Emory University
Medical College of Pennsylvania
-
2005
Obesity Research Editor’s Choice Reviewer Award -
1994
NJ Agricultural Experiment Station Research Award
Cardiovascular, Cell Biology, Cellular Differentiation, Diabetes, Extracellular Matrix, Fibrosis, Gene Expressions, Genomics, Growth, Hormones, Insulin, Lipid Signaling, Microarray, Obesity, Oxidative Phosphorylation, Oxidative Stress, Protein Transl
Central obesity, especially visceral obesity, is associated with higher risk for metabolic disease such as Type 2 diabetes. On the other hand, peripheral obesity, i.e. ‘pear-shaped’ with more storage around hips and thighs decreases risk of metabolic disease, independent of total body fat. The goal of my lab’s research is to understand the physiological, cellular and molecular mechanisms that regulate adipose tissue distribution and its relationship to metabolic health. We use in vivo and in vitro approaches to understand the differential sensitivity of visceral and subcutaneous adipose tissues to the lipogenic and anti-inflammatory effects of glucocorticoids. We are also building on our early studies of metabolic differences among fat depots in men and women with analyses of genes and secreted proteins that are expressed in a sex- and depot-dependent manner. Using primary cell culture and organ culture, our basic research focuses on translationally important questions in adipose tissue biology: 1) how the adipocyte functions as an endocrine cell that can detect the level of body fat and response to the metabolic needs of the organism, and 2) mechanisms that control human adipose tissue remodeling and growth, 3) mechanisms regulating lipid droplet biology and fat oxidation in human adipocytes. A long-term goal is to develop novel therapies for obesity and related diseases by understanding the interaction of genetic and nutritional influences on susceptibility to obesity and metabolic disease, and sex- and racial differences in these relationships.
Karastergiou K, Bredella MA, Lee MJ, Smith SR, Fried SK, Miller KK. Growth hormone receptor expression in human gluteal versus abdominal subcutaneous adipose tissue: Association with body shape. Obesity (Silver Spring, Md.) 2016 May; 24(5).
Fried SK, Lee MJ, Karastergiou K. Shaping fat distribution: New insights into the molecular determinants of depot- and sex-dependent adipose biology. Obesity (Silver Spring, Md.) 2015 Jul; 23(7).
Jedrychowski MP, Liu L, Laflamme CJ, Karastergiou K, Meshulam T, Ding SY, Wu Y, Lee MJ, Gygi SP, Fried SK, Pilch PF. Adiporedoxin, an upstream regulator of ER oxidative folding and protein secretion in adipocytes. Molecular metabolism 2015 Nov; 4(11).
Jang H, Bhasin S, Guarneri T, Serra C, Schneider M, Lee MJ, Guo W, Fried SK, Pencina K, Jasuja R. The Effects of a Single Developmentally Entrained Pulse of Testosterone in Female Neonatal Mice on Reproductive and Metabolic Functions in Adult Life. Endocrinology 2015 Oct; 156(10).
Lillis AP, Muratoglu SC, Au DT, Migliorini M, Lee MJ, Fried SK, Mikhailenko I, Strickland DK. LDL Receptor-Related Protein-1 (LRP1) Regulates Cholesterol Accumulation in Macrophages. PloS one 2015; 10(6).
Lillis AP, Muratoglu SC, Au DT, Migliorini M, Lee MJ, Fried SK, Mikhailenko I, Strickland DK. Correction: LDL Receptor-Related Protein-1 (LRP1) Regulates Cholesterol Accumulation in Macrophages. PloS one 2016; 11(1).
Lee MJ, Yang RZ, Karastergiou K, Smith SR, Chang JR, Gong DW, Fried SK. Low expression of the GILZ may contribute to adipose inflammation and altered adipokine production in human obesity. Journal of lipid research 2016 Jul; 57(7).
Gajda AM, Zhou YX, Agellon LB, Fried SK, Kodukula S, Fortson W, Patel K, Storch J. Direct comparison of mice null for liver or intestinal fatty acid-binding proteins reveals highly divergent phenotypic responses to high fat feeding. The Journal of biological chemistry 2013 Oct; 288(42).
Lee MJ, Fried SK. The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. International journal of obesity (2005) 2014 Sep; 38(9).
Ding SY, Lee MJ, Summer R, Liu L, Fried SK, Pilch PF. Pleiotropic effects of cavin-1 deficiency on lipid metabolism. The Journal of biological chemistry 2014 Mar; 289(12).
Lee MJ, Fried SK. Optimal protocol for the differentiation and metabolic analysis of human adipose stromal cells. Methods in enzymology 2014; 538.
Lee MJ, Fried SK. Reply to Armani et al. Can cortisol stimulate adipogenesis without the glucocorticoid receptor?. International journal of obesity (2005) 2014 Dec; 38(12).
Divoux A, Karastergiou K, Xie H, Guo W, Perera RJ, Fried SK, Smith SR. Identification of a novel lncRNA in gluteal adipose tissue and evidence for its positive effect on preadipocyte differentiation. Obesity (Silver Spring, Md.) 2014 Aug; 22(8).
Karastergiou K, Fried SK. Multiple adipose depots increase cardiovascular risk via local and systemic effects. Current atherosclerosis reports 2013 Oct; 15(10).
Chakrabarti P, Kim JY, Singh M, Shin YK, Kim J, Kumbrink J, Wu Y, Lee MJ, Kirsch KH, Fried SK, Kandror KV. Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. Molecular and cellular biology 2013 Sep; 33(18).
Watkins AA, Yasuda K, Wilson GE, Aprahamian T, Xie Y, Maganto-Garcia E, Shukla P, Oberlander L, Laskow B, Menn-Josephy H, Wu Y, Duffau P, Fried SK, Lichtman AH, Bonegio RG, Rifkin IR. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. Journal of immunology (Baltimore, Md. : 1950) 2015 Feb; 194(4).
.;.
Karastergiou K, Fried SK, Xie H, Lee MJ, Divoux A, Rosencrantz MA, Chang RJ, Smith SR. Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. The Journal of clinical endocrinology and metabolism 2013 Jan; 98(1).
Nimitphong H, Holick MF, Fried SK, Lee MJ. 25-hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ promote the differentiation of human subcutaneous preadipocytes. PloS one 2012; 7(12).
Grahn TH, Zhang Y, Lee MJ, Sommer AG, Mostoslavsky G, Fried SK, Greenberg AS, Puri V. FSP27 and PLIN1 interaction promotes the formation of large lipid droplets in human adipocytes. Biochemical and biophysical research communications 2013 Mar; 432(2).
Lee MJ, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochimica et biophysica acta 2014 Mar; 1842(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Fried did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.